TransMedics Group, Inc. $TMDX Shares Sold by Sandhill Capital Partners LLC

Key Points

• Sandhill Capital Partners LLC reduced its stake in TransMedics Group, Inc. by 98%, selling 174,383 shares and leaving them with only 3,627 shares valued at $244,000.
• TransMedics reported $0.92 earnings per share for the last quarter, significantly exceeding analyst expectations of $0.48, along with a revenue increase of 37.7% year-over-year.
• Institutional investors collectively own 99.67% of TransMedics' stock, highlighting strong interest from major investment funds.

Sandhill Capital Partners LLC reduced its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 98.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,627 shares of the company's stock after selling 174,383 shares during the quarter. Sandhill Capital Partners LLC's holdings in TransMedics Group were worth $244,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. NBC Securities Inc. bought a new position in shares of TransMedics Group during the first quarter valued at approximately $25,000. Hager Investment Management Services LLC increased its position in shares of TransMedics Group by 38.3% during the first quarter. Hager Investment Management Services LLC now owns 740 shares of the company's stock valued at $50,000 after acquiring an additional 205 shares in the last quarter. CWM LLC lifted its stake in TransMedics Group by 20.1% during the 1st quarter. CWM LLC now owns 925 shares of the company's stock valued at $62,000 after acquiring an additional 155 shares during the period. GAMMA Investing LLC lifted its stake in TransMedics Group by 551.7% during the 1st quarter. GAMMA Investing LLC now owns 1,564 shares of the company's stock valued at $105,000 after acquiring an additional 1,324 shares during the period. Finally, Sava Infond d.o.o. lifted its stake in TransMedics Group by 46.7% during the 1st quarter. Sava Infond d.o.o. now owns 2,200 shares of the company's stock valued at $148,000 after acquiring an additional 700 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, Director Edward M. Basile sold 5,000 shares of the business's stock in a transaction that occurred on Tuesday, May 27th. The shares were sold at an average price of $126.45, for a total value of $632,250.00. Following the sale, the director directly owned 2,866 shares of the company's stock, valued at approximately $362,405.70. The trade was a 63.56% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Anil P. Ranganath sold 686 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $139.80, for a total transaction of $95,902.80. Following the transaction, the insider owned 13,955 shares of the company's stock, valued at $1,950,909. This trade represents a 4.69% decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Piper Sandler reaffirmed an "overweight" rating and issued a $145.00 target price (up previously from $125.00) on shares of TransMedics Group in a research report on Wednesday, June 4th. Needham & Company LLC reaffirmed a "hold" rating on shares of TransMedics Group in a research report on Tuesday, June 17th. Morgan Stanley lifted their target price on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an "equal weight" rating in a research report on Friday, August 1st. Oppenheimer lifted their target price on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Finally, Canaccord Genuity Group upped their target price on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research report on Tuesday, July 15th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, TransMedics Group presently has a consensus rating of "Moderate Buy" and an average target price of $123.00.

TransMedics Group Trading Up 0.9%

TMDX stock traded up $1.04 during mid-day trading on Friday, reaching $119.85. The company had a trading volume of 1,032,110 shares, compared to its average volume of 1,241,494. The company has a debt-to-equity ratio of 1.61, a current ratio of 9.86 and a quick ratio of 9.17. The company has a market capitalization of $4.09 billion, a PE ratio of 62.10 and a beta of 2.09. The firm has a 50 day moving average of $121.65 and a 200 day moving average of $101.32. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $177.37.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.44. The company had revenue of $157.37 million during the quarter, compared to analysts' expectations of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. TransMedics Group's revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.35 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. On average, equities analysts predict that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.